Latest Media Releases (Page 5) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Paragon Care - PGC-CH2 Merger Presentation (ASX:PGC)

To view the presentation, download the attached PDF.

Paragon Care - Reinstatement to Official Quotation (ASX:PGC)

The suspension of trading in the securities of Paragon Care Limited (‘PGC’) will be lifted immediately following the release by PGC of its Appendix 4D and half year accounts for the peri...read more

Austco Healthcare Investor Presentation (ASX:AHC)

To view the presentation, download the attached PDF.

Paragon Care - S&P DJI Announces March 2024 Quarterly Rebalance (ASX:PGC)

S&P Dow Jones Indices announced today the changes in the S&P/ASX Indices, effective prior to the open of trading on Monday, March 18, 2024, as a result of the March quarterly review. For ...read more

Paragon Care - Merger of PGC and CH2 Holdings (ASX:PGC)

A transformative merger between ParagonCare and CH2 creating a leading healthcare wholesaler, distributor and manufacturer operating across growing healthcare markets in the Asia Pacific region. ...read more

Paragon Care - Suspension from Quotation (ASX:PGC)

The securities of the following entities will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Friday, 1 March 2024, for not lodging the relevant periodic ...read more

Paragon Care - Appendix 4D and Half Year Report (ASX:PGC)

To view the report, download the attached PDF.

Radiopharm Theranostics - Half Yearly Report and Accounts (ASX:RAD)

To view the report, download the attached PDF.

Radiopharm Theranostics - Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301 (ASX:RAD)

-- First Pancreatic Cancer participant dosed at the Montefiore Medical Center, New York, USA -- Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301 -- A total...read more

Chimeric Therapeutics - Half Yearly Report and Accounts (ASX:CHM)

To view the report, download the attached PDF.

Radiopharm Theranostics - Pilot Study Validates RAD Terbium-161 Radiotherapeutics (ASX:RAD)

-- Publication of first head-to-head data shows superior Therapeutic Index with Tb161 vs Lu177 in 6 metastatic castration-resistant prostate cancer patients. -- This Pilot study validates Radiophar...read more

Immutep - Half Yearly Report and Accounts (ASX:IMM)

To view the report, download the attached PDF.

Next Science - FY23 Annual Result Investor Presentation (ASX:NXS)

To view the presentation, download the attached PDF.

Next Science reports FY23 Result (ASX:NXS)

-- Revenue of US$22.2m, up 89% year-on-year (yoy) with 2H FY23 revenue of US$12.1m in line with 2H FY23 guidance of US$12m-14m provided in October 2023 -- Product Sales of US$22.1m, up 90% yoy refl...read more

Next Science - Appendix 4E / FY23 Financial Statements (ASX:NXS)

To view the appendix, download the attached PDF.

Viewing: 61 - 75 of 200 Previous | Next